PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

'Smart drug' targets new mutation, dramatically shrinks aggressive sarcoma and lung cancer

Patient's response was predicted by test for mutant protein in tumor cells

'Smart drug' targets new mutation, dramatically shrinks aggressive sarcoma and lung cancer
2010-10-28
(Press-News.org) BOSTON--A new oral drug caused dramatic shrinkage of a patient's rare, aggressive form of soft-tissue cancer that was driven by an abnormally activated protein, physician-scientists from Dana-Farber Cancer Institute report in the Oct. 28 issue of the New England Journal of Medicine.

A second patient who had a similar tumor that was not fueled by the mutant protein, called ALK (named for the first disease in which it was found, anaplastic lymphoma kinase), failed to respond to the drug, said the researchers, confirming the inhibitor's specificity for the abnormal protein. The findings also highlight the value of "personalized medicine" gene-testing strategies to predict the best drug treatment for an individual's particular, genetically defined cancer.

The patient described in the NEJM Brief Report is a 44-year-old man diagnosed in 2007 with inflammatory myofibroblastic tumor (IMT), a type of sarcoma that typically develops in the chest or abdomen in children and young adults.

In approximately half the cases of IMT, ALK is fused to a different protein in the patients' cancer cells, spurring cancer development. The patient had been treated with standard chemotherapy drugs followed by the targeted compound Gleevec, but the cancer returned in the form of multiple tumors.

James Butrynski, MD and Geoffrey Shapiro, MD, PhD, Dana-Farber oncologists and the first and senior authors of the report, respectively, offered the patient participation in a Phase 1 trial of an experimental drug, crizotinib, which blocks ALK activity, as well as that of another oncogene, MET, that is abnormally activated in a number of cancers.

Crizotinib treatment shrank the tumors by more than 50 percent – technically called a "partial response." After several months of crizotinib, in December 2008, some of the tumors became resistant to the drug and started growing again. These tumors, as well as tumors still responsive to crizotinib, were removed surgically. Crizotinib was resumed after the surgery, and the patient remains without evidence of disease as of September 2010, according to the investigators.

The activity of crizotinib goes beyond this rare sarcoma. The current report accompanies a paper in the same journal describing striking activity of crizotinib in a group of patients with non-small cell lung cancers (NSCLC) containing the abnormal ALK protein. Researchers from Massachusetts General Hospital, Dana-Farber/Brigham and Women's Cancer Center, and other hospitals gave crizotinib to 82 patients after standard drugs failed to halt the tumors' growth. As part of the personalized medicine effort ongoing in the Dana-Farber/Brigham and Women's Cancer Center Thoracic Oncology Program, patients with abnormal ALK were identified for the trial, underscoring the importance of tumor profiling to match drug with patient.

Results showed that 47 patients had tumor shrinkage (complete disappearance in one patient) and the cancer stopped growing in 27 patients. The ALK rearrangements are found in a small subset, about 5 percent, of patients with NSCLC, but scientists are searching for other cancers that may also be susceptible to the ALK inhibitor.

Shapiro noted that even highly successful targeted drugs like crizotinib are vulnerable to tumors' developing resistance against them. In fact, the IMT patient's tumors that developed resistance to crizotinib and were removed surgically have been studied by one of the reports co-authors, Pasi Janne, MD, PhD, also of Dana-Farber. In a paper appearing simultaneously in Cancer Research, Janne and his colleagues have identified a secondary mutation in ALK in the patient's tumor that conferred resistance to crizotinib. Furthermore, in work recently published by Janne, Shapiro and their Dana-Farber colleague, Kwok-Kin Wong, MD, PhD, the abnormal ALK proteins, including the protein with the secondary mutation that was resistant to crizotinib, were found to depend on a cellular chaperone, called Hsp90, for their stability. Inhibitors of Hsp90 are currently under clinical evaluation and have been shown to cause destruction of the aberrant ALK proteins.

Crizotinib is one of many targeted agents currently being evaluated by the Early Drug Development Center within the Experimental Therapeutics Program at Dana-Farber, with the aim of translating the best science into effective new therapies for patients with many forms of cancer that can be defined by sophisticated new molecular profiling techniques.



INFORMATION:

Authors of the NEJM Brief Report, in addition to Shapiro, Butrynski, and Janne, include co-senior author George Demetri, MD, and Marzia Capelletti, PhD, Dana-Farber; Nikhil Ramaiya, MD, Dana-Farber/Brigham and Women's; and Jason Hornick, MD, PhD, Paola Dal Sin, PhD, and Scott Rodig, MD, PhD, Brigham and Women's, as well as researchers from other hospitals and Pfizer Global Research and Development.

The work was supported in part by Pfizer as well as the National Institutes of Health.

Dana-Farber Cancer Institute (www.dana-farber.org) is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute. It provides adult cancer care with Brigham and Women's Hospital as Dana-Farber/Brigham and Women's Cancer Center and it provides pediatric care with Children's Hospital Boston as Dana-Farber/Children's Hospital Cancer Center. Dana-Farber is the top ranked cancer center in New England, according to U.S. News & World Report, and one of the largest recipients among independent hospitals of National Cancer Institute and National Institutes of Health grant funding.


[Attachments] See images for this press release:
'Smart drug' targets new mutation, dramatically shrinks aggressive sarcoma and lung cancer

ELSE PRESS RELEASES FROM THIS DATE:

New methods detect subtleties in human genomes' repetitive landscapes

New methods detect subtleties in human genomes repetitive landscapes
2010-10-28
Scientists have invented methods to scout the human genome's repetitive landscapes, where DNA sequences are highly identical and heavily duplicated. These advances, as reported today in Science, can identify subtle but important differences among people in the number and content of repeated DNA segments. These copy number variations partly account for the normal diversity among people. Copy number variations might also be why some people, and not others, have certain disorders or disease susceptibilities, and might also determine how severely they are affected. Until ...

Certain cancer therapies' success depends on presence of immune cell, Stanford study shows in mice

2010-10-28
STANFORD, Calif. — The immune system may play a critical role in ensuring the success of certain types of cancer therapies, according to a new study by researchers at the Stanford University School of Medicine. The research showed treatments that disable cancer-promoting genes called oncogenes are much more successful in eradicating tumors in the presence of a signaling molecule secreted by kind of immune cell called a T helper cell. The finding is important because many drugs now in use in humans are often tested in lab animals with weakened immune systems and many human ...

Controlling individual cortical nerve cells by human thought

Controlling individual cortical nerve cells by human thought
2010-10-28
PASADENA, Calif.—Five years ago, neuroscientist Christof Koch of the California Institute of Technology (Caltech), neurosurgeon Itzhak Fried of UCLA, and their colleagues discovered that a single neuron in the human brain can function much like a sophisticated computer and recognize people, landmarks, and objects, suggesting that a consistent and explicit code may help transform complex visual representations into long-term and more abstract memories. Now Koch and Fried, along with former Caltech graduate student and current postdoctoral fellow Moran Cerf, have found ...

Revising the timeline for deadly pancreatic cancer

2010-10-28
Pancreatic tumors are one of the most lethal cancers, with fewer than five percent of patients surviving five years after diagnosis. But a new study that peers deeply into the genetics of pancreatic cancer presents a bit of good news: an opportunity for early diagnosis. In contrast to earlier predictions, many pancreatic tumors are, in fact, slow growing, taking nearly 20 years to become lethal after the first genetic perturbations appear. "There have been two competing theories explaining why pancreatic cancers are so lethal," says Bert Vogelstein, the Howard Hughes ...

1000 Genomes Project publishes analysis of completed pilot phase

2010-10-28
Small genetic differences between individuals help explain why some people have a higher risk than others for developing illnesses such as diabetes or cancer. Today in the journal Nature, the 1000 Genomes Project, an international public-private consortium, published the most comprehensive map of these genetic differences, called variations, estimated to contain approximately 95 percent of the genetic variation of any person on Earth. Researchers produced the map using next-generation DNA sequencing technologies to systematically characterize human genetic variation ...

Large-scale fish farm production offsets environmental gains

2010-10-28
VICTORIA – Industrial-scale aquaculture production magnifies environmental degradation, according to the first global assessment of the effects of marine finfish aquaculture (e.g. salmon, cod, turbot and grouper) released today. This is true even when farming operations implement the best current marine fish farming practices. Dr. John Volpe and his team at the University of Victoria developed the Global Aquaculture Performance Index (GAPI), an unprecedented system for objectively measuring the environmental performance of fish farming. "Scale is critical," said Dr. ...

Spiral galaxies stripped bare

Spiral galaxies stripped bare
2010-10-28
HAWK-I [1] is one of the newest and most powerful cameras on ESO's Very Large Telescope (VLT). It is sensitive to infrared light, which means that much of the obscuring dust in the galaxies' spiral arms becomes transparent to its detectors. Compared to the earlier, and still much-used, VLT infrared camera ISAAC, HAWK-I has sixteen times as many pixels to cover a much larger area of sky in one shot and, by using newer technology than ISAAC, it has a greater sensitivity to faint infrared radiation [2]. Because HAWK-I can study galaxies stripped bare of the confusing effects ...

Singapore scientist leads team to discover origin of brain immune cells

2010-10-28
A team of international scientists led by Dr Florent Ginhoux of the Singapore Immunology Network (SIgN) of Singapore's Agency of Science, Technology and Research (A*STAR), have made a breakthrough that could lead to a better understanding of many neurodegenerative and inflammatory brain disorders. Their work, published in top scientific journal Science, uncovered the origins of microglia, which are white blood cells specific to the brain, and showed that, in mice, microglia had a completely different origin than other white blood cells. This understanding may lead to the ...

Narcotics and diagnostics overused in treatment of chronic neck pain

2010-10-28
Duke University and University of North Carolina (UNC) researchers report in the November issue of Arthritis Care & Research that narcotics and diagnostic testing are overused in treating chronic neck pain. Their findings indicate clinicians may overlook more effective treatments for neck pain, such as therapeutic exercise. According to reviews cited in the study, evidence to support the effectiveness of therapeutic exercise in treating chronic neck pain is good, yet only 53% of subjects were prescribed such exercise. This information was based upon reported data from a ...

Learning the truth not effective in battling rumors about NYC mosque, study finds

2010-10-28
COLUMBUS, Ohio – Evidence is no match against the belief in false rumors concerning the proposed Islamic cultural center and mosque near Ground Zero in New York City, a new study finds. Researchers at Ohio State University found that fewer than one-third of people who had previously heard and believed one of the many rumors about the proposed center changed their minds after reading overwhelming evidence rejecting the rumor. The false rumor that researchers used in the study was that Feisal Abdul Rauf, the Imam backing the proposed Islamic cultural center and mosque, ...

LAST 30 PRESS RELEASES:

Testing thousands of RNA enzymes helps find first ‘twister ribozyme’ in mammals

Groundbreaking study provides new evidence of when Earth was slushy

International survey of more than 1600 biomedical researchers on the perceived causes of irreproducibility of research results

Integrating data from different experimental approaches into one model is challenging – this study presents a community-based, full-scale in silico model of the rat hippocampal CA1 region that integra

SwRI awarded grant to characterize Las Moras Springs watershed

Water overuse in MATOPIBA could mean failure to meet up to 40% of local demand for crop irrigation

An extra year of education does not protect against brain aging

Researchers from Uppsala and Magdeburg obtain an ERC Synergy Grant to advance cancer immunotherapy

Deaf male mosquitoes don’t mate

Recognizing traumatic brain injury as a chronic condition fosters better care over the survivor’s lifetime

SwRI’s Dr. James Walker receives Distinguished Scientist Award from Hypervelocity Impact Society

A mother’s health problems pose a risk to her children

Ensuring a bright future for diamond electronics and sensors

The American Pediatric Society selects Dr. Maria Trent as the Recipient of the 2025 David G. Nichols Health Equity Award

The first 3D view of the formation and evolution of globular clusters

Towards a hydrogen-powered future: highly sensitive hydrogen detection system

Scanning synaptic receptors: A game-changer for understanding psychiatric disorders

High-quality nanomechanical resonators with built-in piezoelectricity

ERC Synergy Grants for 57 teams tackling major scientific challenges

Nordic research team receives €13 million to explore medieval book culture 

The origin of writing in Mesopotamia is tied to designs engraved on ancient cylinder seals

Explaining science through dance

Pioneering neuroendocrinologist's century of discovery launches major scientific tribute series

Gendered bilingualism in post-colonial Korea

Structural safety monitoring of buildings with color variations

Bio-based fibers could pose greater threat to the environment than conventional plastics

Bacteria breakthrough could accelerate mosquito control schemes

Argonne to help drive AI revolution in astronomy with new institute led by Northwestern University

Medicaid funding for addiction treatment hasn’t curbed overdose deaths

UVA co-leads $2.9 million NIH investigation into where systems may fail people with disabilities

[Press-News.org] 'Smart drug' targets new mutation, dramatically shrinks aggressive sarcoma and lung cancer
Patient's response was predicted by test for mutant protein in tumor cells